These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 3455613

  • 1. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease.
    Vega E, Gonzalez D, Ghiringhelli G, Mautalen C.
    J Bone Miner Res; 1987 Aug; 2(4):267-71. PubMed ID: 3455613
    [Abstract] [Full Text] [Related]

  • 2. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
    Chakravarty K, Merry P, Scott DG.
    J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320
    [Abstract] [Full Text] [Related]

  • 3. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J.
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [Abstract] [Full Text] [Related]

  • 4. Determinants of remission of Paget's disease of bone.
    Patel S, Stone MD, Coupland C, Hosking DJ.
    J Bone Miner Res; 1993 Dec; 8(12):1467-73. PubMed ID: 8304048
    [Abstract] [Full Text] [Related]

  • 5. The effects of intravenous alendronate in Paget's disease of bone.
    O'Doherty DP, McCloskey EV, Vasikaran S, Khan S, Kanis JA.
    J Bone Miner Res; 1995 Jul; 10(7):1094-100. PubMed ID: 7484285
    [Abstract] [Full Text] [Related]

  • 6. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
    O'Doherty DP, Bickerstaff DR, McCloskey EV, Hamdy NA, Beneton MN, Harris S, Mian M, Kanis JA.
    J Bone Miner Res; 1990 May; 5(5):483-91. PubMed ID: 2195845
    [Abstract] [Full Text] [Related]

  • 7. Paget's disease of bone treated in five days with AHPrBP (APD) per Os.
    Thiébaud D, Jaeger P, Burckhardt P.
    J Bone Miner Res; 1987 Feb; 2(1):45-52. PubMed ID: 3455156
    [Abstract] [Full Text] [Related]

  • 8. Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD).
    Stone MD, Hawthorne AB, Kerr D, Webster G, Hosking DJ.
    J Bone Miner Res; 1990 Dec; 5(12):1231-5. PubMed ID: 2075835
    [Abstract] [Full Text] [Related]

  • 9. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
    Stuckey BG, Lim EM, Kent GN, Ward LC, Gutteridge DH.
    J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
    [Abstract] [Full Text] [Related]

  • 10. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.
    Devlin RD, Retallack RW, Fenton AJ, Grill V, Gutteridge DH, Kent GN, Prince RL, Worth GK.
    J Bone Miner Res; 1994 Jan; 9(1):81-5. PubMed ID: 8154313
    [Abstract] [Full Text] [Related]

  • 11. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR.
    J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
    [Abstract] [Full Text] [Related]

  • 12. Aminohexane diphosphonate in the treatment of Paget's disease of bone.
    Atkins RM, Yates AJ, Gray RE, Urwin GH, Hamdy NA, Beneton MN, Rosini S, Kanis JA.
    J Bone Miner Res; 1987 Aug; 2(4):273-9. PubMed ID: 3455614
    [Abstract] [Full Text] [Related]

  • 13. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BG, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH.
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD.
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile.
    Vega E, Mautalen C, Roldán EJ, Pérez Lloret A.
    Drugs Exp Clin Res; 1994 Feb; 20(3):103-8. PubMed ID: 7956716
    [Abstract] [Full Text] [Related]

  • 19. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone.
    Harinck HI, Bijvoet OL, Blanksma HJ, Dahlinghaus-Nienhuys PJ.
    Clin Orthop Relat Res; 1987 Apr; (217):79-98. PubMed ID: 2951049
    [Abstract] [Full Text] [Related]

  • 20. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
    Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL.
    Br Med J (Clin Res Ed); 1987 Nov 21; 295(6609):1301-5. PubMed ID: 3120987
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.